YOLFTbeta
Percheron Therapeutics Ltd

Percheron Therapeutics Ltd

PER · AU · Healthcare / Drug Manufacturers - Specialty & Generic

0.003AUD-0.00 (-25.00%)

Price History

Full chart

Market Stats

Previous Close0.004
Open0.003
Day Range0.003 – 0.003
52-Week Range0.002 – 0.011
Volume1.11K
Market Cap7.29M
P/E (TTM)0.00
Forward P/E9.35
EPS0.00
Dividend Yield0.00%
Beta1.10
50-Day Avg0.0043
200-Day Avg0.0053

About

Percheron Therapeutics Limited engages in the research and development of antisense pharmaceuticals for cancer and rare diseases in Australia. Its products pipeline includes HMBD-002, a recombinant humanised monoclonal IgG4 antibody, which completed phase I clinical trial to treat to human v-domain immunoglobulin suppressor of T-cell activation (VISTA). The company was formerly known as Antisense Therapeutics Limited and changed its name to Percheron Therapeutics Limited in December 2023. Percheron Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEODr. Michael Baker
  • Employees0
  • HeadquartersCollins Place, Melbourne, VIC, Australia, 3000, Australia
  • Websitehttps://percherontx.com

Leadership

  • Ms. Deborah Ambrosini B.Com., F.C.A.CFO, Company Secretary & Director · b. 1974
  • Dr. Michael BakerChief Executive Director
  • Ms. Valentina Dubljevic BSc, GAICD, MBBChief Technology Officer
  • Dr. Eugene P. Kennedy F.A.C.S., M.D.Chief Medical Officer · b. 1969

Financials

Income Statement

Currency: AUD2001-06-302002-06-302003-06-302004-06-302005-06-302006-06-302007-06-302008-06-302009-06-302010-06-302011-06-302012-06-302013-06-302014-06-302015-06-302016-06-302017-06-302018-06-302019-06-302020-06-302021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Total Revenue11.00K409.00K448.00K1.34M848.00K408.00K-3.41K6.40M255.00K103.00K91.00K102.00K203.00K83.00K3.86M1.00M69.11K25.55K66.17K30.53K4.18K34.18K384.92K---
Growth (%)-+3618.18%+9.54%+199.33%-36.76%-51.89%-100.84%+187864.08%-96.02%-59.61%-11.65%+12.09%+99.02%-59.11%+4555.41%-74.12%-93.09%-63.03%+158.98%-53.86%-86.31%+717.70%+1026.16%---
Cost of Revenue11.00K61.00K72.00K115.00K200.00K321.00K188.00K92.00K194.00K713.91K153.89K182.70K231.67K9.75K205.35K311.50K202.92K6.41K5.38K107.60K103.32K89.22K95.20K79.42K67.98K219.56K
Gross Profit-------3.41K6.40M--713.91K-153.89K-182.70K-231.67K-9.75K3.86M1.00M69.11K-6.41K-5.38K-107.60K-103.32K-89.22K-95.20K-79.42K-67.98K-219.56K
Gross Margin------100.00%100.00%--693.11%-169.11%-179.12%-114.12%-11.75%100.00%100.00%100.00%-25.10%-8.13%-352.44%-2471.75%-261.02%-24.73%---
Operating Expense------5.60M7.52M-2.80M1.76M1.72M2.44M4.25M3.89M4.07M3.29M2.61M3.58M6.56M8.58M7.52M13.25M14.80M16.64M5.40M
Operating Income-271.11K-6.72M-6.55M-6.32M-7.11M-5.95M-5.60M-1.12M-4.60M-3.51M-1.91M-1.90M-2.67M-4.26M-24.92K-3.07M-3.22M-2.62M-3.58M-6.67M-8.68M-7.61M-13.34M-14.88M-16.71M-5.62M
Operating Margin-2464.65%-1643.27%-1463.05%-471.50%-838.92%-1457.66%164370.28%-17.52%-1803.60%-3411.56%-2102.35%-1863.71%-1315.16%-5127.60%-0.65%-307.24%-4655.44%-10254.96%-5415.05%-21835.22%-207734.00%-22268.08%-3466.95%---
EBITDA-271.11K-5.64M-4.81M-5.05M-5.84M-4.49M-5.14M-1.11M-4.59M-3.86M-2.43M-2.85M-3.75M-4.25M-16.75K-3.07M-3.21M-2.61M-3.58M-6.56M-8.58M-7.52M-13.25M-11.84M-16.27M-5.40M
EBITDA Margin-2464.65%-1380.02%-1073.67%-376.24%-688.27%-1100.90%150845.25%-17.38%-1800.58%-3751.68%-2668.78%-2797.70%-1849.07%-5115.85%-0.43%-306.65%-4648.36%-10229.86%-5406.92%-21482.78%-205262.25%-22007.05%-3442.22%---
Net Income-393.74K-6.32M-6.11M-4.61M-6.27M-5.46M-4.84M-2.14M-2.65M-3.42M-1.81M-1.80M-2.45M-3.01M706.92K-2.51M-2.75M-2.33M-2.94M-5.91M-8.06M-5.81M-11.38M-11.92M-14.92M-4.79M
Net Income Margin-3579.45%-1545.48%-1363.37%-343.75%-738.90%-1338.82%141900.32%-33.39%-1039.11%-3325.12%-1992.91%-1765.96%-1209.28%-3630.45%18.30%-251.44%-3985.82%-9123.35%-4449.90%-19352.12%-192838.25%-17003.54%-2956.41%---
R&D235.02K5.13M3.73M3.82M4.47M2.99M3.37M5.13M1.85M1.49M646.54K1.12M1.55M2.15M1.68M1.85M1.10M975.40K1.09M1.90M4.91M4.54M10.16M10.70M10.77M2.09M
R&D as % of Total Revenue2136.54%1254.87%832.28%285.11%527.57%732.11%-98964.14%80.21%725.29%1444.61%710.48%1093.61%761.53%2586.10%43.37%184.75%1597.29%3817.62%1648.31%6221.16%117544.04%13268.27%2640.15%---
Interest Expense04.71K1.52K000000000000000012.54K10.73K11.91K8.15K3.60K14.93K15.34K
Interest Expense % of Total Revenue0.00%1.15%0.34%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%41.06%256.79%34.84%2.12%---

Balance Sheet

Currency: AUD2001-06-302002-06-302003-06-302004-06-302005-06-302006-06-302007-06-302008-06-302009-06-302010-06-302011-06-302012-06-302013-06-302014-06-302015-06-302016-06-302017-06-302018-06-302019-06-302020-06-302021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Total Assets20.09M15.33M11.98M18.15M11.22M9.12M8.05M9.87M4.99M1.82M2.44M5.69M5.20M2.66M7.67M5.33M2.54M4.80M3.70M5.35M7.00M22.44M12.84M14.53M12.44M8.22M
Total Liabilities54.46K1.85M364.40K1.02M357.72K323.03K2.03M3.53M1.06M471.43K417.74K423.29K554.10K569.13K581.44K750.20K685.65K580.86K888.84K821.23K1.27M1.30M2.87M5.17M2.43M692.18K
Total Equity20.03M13.48M11.62M17.13M10.86M8.79M6.02M6.33M3.93M1.34M2.02M5.27M4.65M2.09M7.09M4.58M1.85M4.22M2.81M4.53M5.73M21.14M9.98M9.36M10.00M7.53M
Cash13.68M9.37M6.55M14.42M8.82M8.24M7.60M6.36M3.08M1.73M2.34M4.97M4.00M1.33M6.83M4.80M1.90M1.90M2.90M4.06M6.02M19.23M10.97M11.87M10.17M2.55M
Total Debt-------------50.00K----135.26K135.26K306.85K227.40K142.10K39.87K25.86K27.79K
Net Debt-13.68M-9.37M-6.55M-14.42M-8.82M-8.24M-7.60M-6.36M-3.08M-1.73M-2.34M-4.97M-4.00M-1.28M-6.83M-4.80M-1.90M-1.90M-2.90M-3.92M-5.71M-19.01M-10.83M-11.83M-10.14M-2.52M

Cash Flow

Currency: AUD2001-06-302002-06-302003-06-302004-06-302005-06-302006-06-302007-06-302008-06-302009-06-302010-06-302011-06-302012-06-302013-06-302014-06-302015-06-302016-06-302017-06-302018-06-302019-06-302020-06-302021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Operating Cash Flow--4.06M--2.21M-5.59M-3.96M-2.68M-3.40M-3.28M-1.34M-1.87M-2.41M-2.83M-3.11M1.27M-2.03M-2.91M-2.30M-2.93M-3.95M-5.83M-7.81M-8.15M-10.12M-15.64M-4.96M
Investing Cash Flow--47.54K-21.65K-17.66K-11.99K-1.59K-11.73K-4.52K-2.12K-13.21K--14.63K-5.58K-10.62K-3.86K-3.86K-15.57K-2.40M2.40M-10.26K-8.35K-3.91K-29.29K-3.61K-7.24K-3.09M
Financing Cash Flow1.04M12.84M4.19M10.10M-2.80K3.38M2.05M2.17M--2.48M5.05M1.84M453.11K4.23M31.07K31.07K4.70M1.53M5.11M7.80M21.02M-85.30K11.02M13.95M1.93M
Capital Expenditure16.00K51.54K23.33K17.66K11.99K1.59K11.73K4.52K2.12K13.21K014.63K5.58K10.62K3.86K3.86K15.57K3410.26K8.35K3.91K29.29K3.61K7.24K7.93K
Free Cash Flow--4.11M-7.02M-2.23M-5.60M-3.96M-2.69M-3.41M-3.29M-1.35M-1.87M-2.42M-2.84M-3.12M1.27M-2.03M-2.93M-2.30M-2.93M-3.96M-5.84M-7.81M-8.18M-10.12M-15.65M-4.97M
Dividends Paid---------------00--97.89K82.39K79.44K----
FCF to OCF-101.27%-100.80%100.21%100.04%100.44%100.13%100.06%100.99%100.00%100.61%100.20%100.34%100.00%100.19%100.53%100.00%100.00%100.26%100.14%100.05%100.36%100.04%100.05%100.16%
Dividend Paid to FCF---------------0.00%0.00%---2.47%-1.41%-1.02%----

Earnings

Report DateFeb 23, 2016Aug 25, 2016Feb 24, 2017Aug 29, 2017Feb 27, 2018Aug 29, 2018Feb 27, 2019Aug 30, 2019Feb 28, 2020Aug 26, 2020Feb 24, 2021Aug 25, 2021Feb 23, 2022Aug 31, 2022Feb 22, 2023Feb 19, 2025Aug 27, 2025
EPS Estimate0.000.000.000.000.000.000.000.000.000.000.00-0.01--0.01-0.01-0.01-
EPS Actual-0.010.00-0.01-0.01-0.01-0.010.000.00-0.010.000.00-0.01-0.010.00-0.01-0.01-0.01
Surprise-----------23.08%-100.00%28.57%28.57%-
Timing------------Pre-marketAfter-hoursAfter-hours-Pre-market

Key Statistics & Ratios

Market Cap7.29M
Enterprise Value5.09M
Trailing P/E0.00
Forward P/E9.35
PEG Ratio0.00
Price / Sales8.64
Price / Book1.21
EPS0.00
Book Value0.005
Revenue (TTM)843.60K
Gross Profit (TTM)664.23K
EBITDA-4.56M
Profit Margin0.00%
Operating Margin-222.63%
Return on Equity-54.66%
Return on Assets-28.90%
Shares Outstanding1.82B
Shares Float1.17B
Beta1.10
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Nov 5, 20131:10